『LMC #68 | Solitary Fibrous Tumors: Research Advances, Treatment Strategies, and Hope for Sarcoma Patients』のカバーアート

LMC #68 | Solitary Fibrous Tumors: Research Advances, Treatment Strategies, and Hope for Sarcoma Patients

LMC #68 | Solitary Fibrous Tumors: Research Advances, Treatment Strategies, and Hope for Sarcoma Patients

無料で聴く

ポッドキャストの詳細を見る

概要

 Dr. Javier Martin-Broto, MD, PhD, a medical oncologist at Fundacion Jimenez Diaz University Hospital in Madrid, joins Dr. Peter Crane to discuss his extensive career in sarcoma care and research. With over 30 years of experience, Dr. Martin-Broto shares how he entered oncology, emphasizing its innovative and research-driven nature. The conversation focuses on solitary fibrous tumors (SFT), including diagnostic shifts from "malignant" to risk-based classifications, the efficacy of anti-angiogenic agents like pazopanib over chemotherapy, and promising preclinical research on BET inhibition and alternative splicing inhibitors like tepotinib. He highlights clinical trial results showing tumor shrinkage, the role of microenvironment in immunotherapy challenges, and strategies like trabectedin plus radiation for bulky tumors. Dr. Martin-Broto stresses multidisciplinary teams, patient advocacy, and access to innovative trials for better outcomes. This episode provides physicians and patients with actionable insights on rare sarcomas, fostering hope through ongoing research.Episode HighlightsJavier's journey into medical oncology: From residency in 1994 to leading sarcoma research and founding the Spanish Sarcoma GroupWhy oncology? Balancing broad medical knowledge with innovation, research, and patient careSolitary fibrous tumors (SFT): Shift from malignant/benign to low/high-risk classifications and metastatic behaviorKey trial insights: Pazopanib's superior efficacy (10+ months PFS in low-risk, 5 months in high-risk) over chemotherapyAnti-angiogenics and rotation strategies: Benefits for metastatic SFT and microenvironment targetingImmunotherapy challenges: Limited PD-1 efficacy but potential in immune modulation via cytokinesPromising research: BET inhibition and alternative splicing inhibitors (e.g., tepotinib) showing tumor shrinkage in trialsCombined therapies: Trabectedin + radiation for bulky or brain SFT, achieving up to 80% reductionPreclinical models: Testing new compounds and organoids for personalized treatmentAdvice for patients: Seek expert multidisciplinary teams, join advocacy groups, and access innovative trialsTop 3 TakeawaysSFT prognosis depends on initial risk level; anti-angiogenics like pazopanib offer better control than chemo, with potential for drug rotation.Emerging therapies like tepotinib (alternative splicing inhibition) show promising tumor shrinkage in ongoing phase II trials.Patients should engage sarcoma experts, multidisciplinary teams, and advocacy groups for access to innovative research and hope.About Dr. Javier Martin-Broto Dr. Javier Martin-Broto is an MD, PhD, and medical oncologist at Fundacion Jimenez Diaz University Hospital in Madrid, specializing in sarcoma care and research for over 30 years. He founded the Spanish Sarcoma Group in 1994 and leads a preclinical team with 40+ projects. His work includes designing 30+ clinical trials, pioneering anti-angiogenic treatments for SFT, and advancing therapies like BET and splicing inhibitors. Dedicated to translational research, he focuses on improving outcomes for rare sarcomas through innovation and patient-centered care.LinkedIn: linkedin.com/in/javiermartinbrotoAbout the Host:Dr. Peter Crane is a board-certified physician, educator, and storyteller with a heart for service and a calling to spotlight doctors who make a difference—in their communities, in medicine, and in the lives they touch.Through Doctors Making a Difference, he brings you into intimate conversations with physicians who have overcome challenges, redefined success, and found purpose in and beyond the clinic. His goal is simple: to help more doctors stay in medicine by showing them what's possible.About the Show:Doctors Making a Difference is more than a podcast—it’s a movement to highlight the good, the gritty, and the deeply human side of medicine.In every episode, Dr. Peter Crane interviews physicians whose stories defy the script. From burnout recovery to bold career pivots, health challenges to quiet leadership, this show honors the truth that healing begins with connection—and doctors, too, deserve to be whole.Visit: doctorsmakingadifference.comLMC Series Note:Living with Metastatic Cancer (LMC) explores the science, decisions, and day-to-day realities of life with advanced disease—through candid physician–patient conversations. The Doctors Making a Difference Podcast is for informational purposes only and does not substitute for medical, legal, or professional advice. Always consult appropriate experts regarding your unique circumstances. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
まだレビューはありません